Published: 1 March 2022
Authors: Raúl Méndez MD, PhD, Laura Feced MD, Victoria Alcaraz-Serrano PhD, Paula González-Jiménez MD, Leyre Bouzas MD, Ricardo Alonso MD, Luis Martínez-Dolz MD, PhD, David Hervás PhD, Laia Fernández-Barat PhD, Antoni Torres MD, PhD, Rosario Menéndez MD, PhD
Source: This abstract has been sourced from NZ Respiratory Research Review Issue 203
Population-based and retrospective studies have shown that risk for cardiovascular events such as arrythmias, ischemic episodes, or heart failure, increase during and after bronchiectasis exacerbations.
What are the risk factors for cardiovascular events (CVE) during and after bronchiectasis exacerbations and their impact on mortality?
This was a post hoc retrospective analysis of a prospective observational study of 250 patients with bronchiectasis at two tertiary care hospitals. Only the first exacerbation was considered for each patient, collecting demographic, comorbidity, and severity data. The main outcomes were the appearance of CVE and mortality. Risk factors for CVE were analyzed using a semi-competing risks model.
During a median follow-up of 35 months, 74 (29.6%) patients had a CVE and 93 (37.2%) died. Semi-competing risk analysis indicated that age, arterial hypertension, COPD, and potentially severe exacerbations significantly increased the risk for developing CVE. Compared with patients without CVE, those with CVE had higher mortality.
Demographic factors and comorbidities are risk factors for the development of CVE after an acute exacerbation of bronchiectasis. The appearance of CVE worsens long-term prognosis.
Link to abstract
NZ Respiratory Research Review Issue 203